Stockscreener 앱 받기
16.30
1.31%
0.21
시간 외 거래:
16.43
0.13
+0.80%
전일 마감가:
$16.09
열려 있는:
$15.79
하루 거래량:
101.02K
Relative Volume:
0.07
시가총액:
$160.69M
수익:
$88.50M
순이익/손실:
$-35.27M
주가수익비율:
-4.9463
EPS:
-3.2954
순현금흐름:
$-23.70M
1주 성능:
-14.88%
1개월 성능:
+27.84%
6개월 성능:
+128.61%
1년 성능:
-0.13%
1일 변동 폭
$15.59
$17.00
1주일 범위
$15.59
$20.20
52주 변동 폭
$3.436
$20.21
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
16.30 | 158.62M | 88.50M | -35.27M | -23.70M | -3.2954 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Singapore
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Zacks Investment Research
Treasury Yields: Can Biodesix Inc navigate macro headwinds2026 Pullbacks & Comprehensive Market Scan Insights - baoquankhu1.vn
Is Biodesix (BDSX) Shares Performing Better Than Other Medical Stocks This Year? - Bitget
Biodesix, Inc. (BDSX) reports Q4 loss, beats revenue estimates - MSN
Wall Street analysts think Biodesix (BDSX) could surge 111.62%: Read this before placing a bet - MSN
Can Biodesix Inc expand into new marketsWeekly Trading Summary & AI Driven Stock Movement Reports - baoquankhu1.vn
Decliners Report: Is Biodesix Inc benefiting from innovation trends2026 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Cannell & Spears LLC Sells 195,326 Shares of Biodesix, Inc. $BDSX - MarketBeat
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference - MarketBeat
Recap Report: What is the dividend yield of Biodesix IncNew Guidance & Accurate Trade Setup Notifications - baoquankhu1.vn
BDSX SEC FilingsBIODESIX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Biodesix Receives 'Moderate Buy' Rating from Analysts - National Today
Biodesix at Barclays Conference: Strategic Growth in Lung Cancer Diagnostics - Investing.com Canada
Biodesix Earnings Call Signals Growth With Caveats - TipRanks
Setup Watch: Is Biodesix Inc in a consolidation phase2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference - MarketBeat
What analysts say about Biodesix Inc stock2025 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target - Yahoo Finance
Wall Street experts predict that Biodesix (BDSX) may climb by 111.62%: Consider this information before making an investment decision - Bitget
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet - Finviz
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
BDSX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monashee Investment Management Cuts Biodesix Stake by 95% - National Today
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Canaccord reiterates Biodesix stock rating on strong Q4 results By Investing.com - Investing.com Canada
Canaccord reiterates Biodesix stock rating on strong Q4 results - Investing.com
Biodesix (BDSX) Q4 2025 Earnings Call Transcript - AOL.com
Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX - MarketBeat
Q4 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
William Blair Upgrades Biodesix (BDSX) - Nasdaq
William Blair Upgrades BDSX (Biodesix, Inc.) to Outperform Feb 2026 - Meyka
Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS - MarketBeat
William Blair Upgrades Biodesix (BDSX) to 'Outperform' | BDSX St - GuruFocus
Biodesix expects 2026 sales to crack $100M - BizWest
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
William Blair Upgrades Biodesix to Outperform From Market Perform - marketscreener.com
GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX - MarketBeat
William Blair upgrades Biodesix stock rating on execution momentum By Investing.com - Investing.com Australia
Biodesix Delivers Strong Q4 and Fiscal 2025 Results - National Today
William Blair upgrades Biodesix stock rating on execution momentum - Investing.com Nigeria
Biodesix Inc (BDSX) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Biodesix, Inc. Q4 Loss Drops - Nasdaq
Biodesix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Biodesix Q4 2025 shows strong revenue growth and positive EBITDA - Investing.com India
BDSX Projects 80% Gross Margin and Revenue Growth for FY26 - GuruFocus
Biodesix Inc (NASDAQ:BDSX) Reports Q4 2025 Earnings Beat and First Adjusted EBITDA Profitability - ChartMill
Biodesix Q4 Earnings Call Highlights - MarketBeat
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):